Anti-IL-3 monoclonal antibodies to treat early stage ARTHRITIS RHEUMATOID in development SuppreMol GmbH, an autoimmune disease professional, today announced a licensing agreement with the University Medical center of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early analysis and treatment of ARTHRITIS RHEUMATOID . SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the business will further validate a highly sensitive human being IL-3 diagnostic assay for patient stratification komentare . SuppreMol’s preclinical candidate SM401 offers demonstrated, in a murine model for RA, that it significantly reduces progression and severity of the disease.
Quarter and Recent Highlights Second quarter 2010 total revenue improved 78 percent to $3.1 million from $1.7 million in the same quarter in 2009 2009. June 30 For the half a year ended, 2010, the business’s total revenue increased 57 percent to $6.4 million from $4.1 million in the first half a year of 2009. The analysis met its principal endpoint of a statistically significant decrease in bladder control problems episodes for both dosages studied. Received a milestone payment from Ferring International Center S.A. Linked to attaining a development-structured milestone under a permit and asset purchase agreement regarding certain intellectual property associated with transdermal gel delivery technology.